DXP Enterprises (NASDAQ:DXPE – Get Free Report) and Capstone Therapeutics (NASDAQ:CAPS – Get Free Report) are both industrials companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.
Risk & Volatility
DXP Enterprises has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Capstone Therapeutics has a beta of -1.52, indicating that its stock price is 252% less volatile than the S&P 500.
Earnings & Valuation
This table compares DXP Enterprises and Capstone Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DXP Enterprises | $2.02 billion | 1.49 | $88.68 million | $5.68 | 34.00 |
| Capstone Therapeutics | $48.11 million | 0.07 | -$21.23 million | ($3.37) | -0.06 |
DXP Enterprises has higher revenue and earnings than Capstone Therapeutics. Capstone Therapeutics is trading at a lower price-to-earnings ratio than DXP Enterprises, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares DXP Enterprises and Capstone Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DXP Enterprises | 4.35% | 18.51% | 5.70% |
| Capstone Therapeutics | -36.51% | -135.83% | -40.51% |
Insider and Institutional Ownership
74.8% of DXP Enterprises shares are owned by institutional investors. Comparatively, 2.5% of Capstone Therapeutics shares are owned by institutional investors. 22.0% of DXP Enterprises shares are owned by company insiders. Comparatively, 39.3% of Capstone Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current ratings and price targets for DXP Enterprises and Capstone Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DXP Enterprises | 0 | 2 | 3 | 0 | 2.60 |
| Capstone Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
DXP Enterprises presently has a consensus price target of $187.00, suggesting a potential downside of 3.16%. Given DXP Enterprises’ stronger consensus rating and higher possible upside, analysts clearly believe DXP Enterprises is more favorable than Capstone Therapeutics.
Summary
DXP Enterprises beats Capstone Therapeutics on 13 of the 14 factors compared between the two stocks.
About DXP Enterprises
DXP Enterprises, Inc., together with its subsidiaries, engages in distributing maintenance, repair, and operating (MRO) products, equipment, and services in the United States and Canada. It operates through three segments: Service Centers (SC), Supply Chain Services (SCS), and Innovative Pumping Solutions (IPS). The SC segment offers MRO products, equipment, and integrated services, including technical expertise and logistics services. It offers a range of MRO products in the rotating equipment, bearing, power transmission, hose, fluid power, metal working, fastener, industrial supply, safety products, and safety services categories. This segment serves customers in the oil and gas, food and beverage, petrochemical, transportation, other general industrial, mining, construction, chemical, municipal, agriculture, and pulp and paper industries. The SCS segment manages procurement and inventory vinventory optimization and management, storeroom management, transaction consolidation and control, vendor oversight and procurement cost optimization, productivity improvement, and customized reporting services. Its programs include SmartAgreement, a procurement solution for various MRO categories; SmartBuy, an on-site or centralized MRO procurement solution; SmartSource, an on-site procurement and storeroom management solution; SmartStore, an e-Catalog solution; SmartVend, an industrial dispensing solution; and SmartServ, an integrated service pump solution. The IPS segment fabricates and assembles custom-made pump packages; remanufactures pumps; and manufactures branded private label pumps. DXP Enterprises, Inc. was founded in 1908 and is based in Houston, Texas.
About Capstone Therapeutics
Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.
Receive News & Ratings for DXP Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DXP Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.
